Arcadia Biosciences Capital Expenditures (CapEx) Growth & History (RKDA)
Arcadia Biosciences's capital expenditures (capex) was $0 for fiscal 2025.
View full Arcadia Biosciences company overviewArcadia Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$16,000 | — |
| 2024 | 2024-12-31 | $16,000 | $11,000 | +220.00% |
| 2023 | 2023-12-31 | $5,000 | −$67,000 | −93.06% |
| 2022 | 2022-12-31 | $72,000 | −$935,000 | −92.85% |
| 2021 | 2021-12-31 | $1.0M | −$1.3M | −56.87% |
| 2020 | 2020-12-31 | $2.3M | $858,000 | +58.09% |
| 2019 | 2019-12-31 | $1.5M | $1.2M | +490.80% |
| 2018 | 2018-12-31 | $250,000 | $171,000 | +216.46% |
| 2017 | 2017-12-31 | $79,000 | −$152,000 | −65.80% |
| 2016 | 2016-12-31 | $231,000 | $80,000 | +52.98% |
| 2015 | 2015-12-31 | $151,000 | $3,000 | +2.03% |
| 2014 | 2014-12-31 | $148,000 | — | — |
Arcadia Biosciences quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | −$3,000 | — |
| Q1 2025 | 2025-03-31 | $0 | −$13,000 | — |
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $3,000 | −$2,000 | −40.00% |
| Q1 2024 | 2024-03-31 | $13,000 | $13,000 | — |
| Q4 2023 | 2023-12-31 | $0 | −$26,000 | — |
| Q3 2023 | 2023-09-30 | $0 | $0 | — |
| Q2 2023 | 2023-06-30 | $5,000 | −$1,000 | −16.67% |
| Q1 2023 | 2023-03-31 | $0 | −$40,000 | — |
| Q4 2022 | 2022-12-31 | $26,000 | −$62,000 | −70.45% |
| Q3 2022 | 2022-09-30 | $0 | −$206,000 | — |
| Q2 2022 | 2022-06-30 | $6,000 | −$222,000 | −97.37% |
| Q1 2022 | 2022-03-31 | $40,000 | −$445,000 | −91.75% |
| Q4 2021 | 2021-12-31 | $88,000 | −$209,000 | −70.37% |
| Q3 2021 | 2021-09-30 | $206,000 | −$83,000 | −28.72% |
| Q2 2021 | 2021-06-30 | $228,000 | −$743,000 | −76.52% |
| Q1 2021 | 2021-03-31 | $485,000 | −$293,000 | −37.66% |
| Q4 2020 | 2020-12-31 | $297,000 | −$302,000 | −50.42% |
| Q3 2020 | 2020-09-30 | $289,000 | −$274,000 | −48.67% |
| Q2 2020 | 2020-06-30 | $971,000 | $744,000 | +327.75% |
| Q1 2020 | 2020-03-31 | $778,000 | $690,000 | +784.09% |
| Q4 2019 | 2019-12-31 | $599,000 | $438,000 | +272.05% |
| Q3 2019 | 2019-09-30 | $563,000 | $542,000 | +2580.95% |
| Q2 2019 | 2019-06-30 | $227,000 | $192,000 | +548.57% |
| Q1 2019 | 2019-03-31 | $88,000 | $55,000 | +166.67% |
| Q4 2018 | 2018-12-31 | $161,000 | $159,000 | +7950.00% |
| Q3 2018 | 2018-09-30 | $21,000 | $2,000 | +10.53% |
| Q2 2018 | 2018-06-30 | $35,000 | $34,000 | +3400.00% |
| Q1 2018 | 2018-03-31 | $33,000 | −$24,000 | −42.11% |
| Q4 2017 | 2017-12-31 | $2,000 | −$7,000 | −77.78% |
| Q3 2017 | 2017-09-30 | $19,000 | −$5,000 | −20.83% |
| Q2 2017 | 2017-06-30 | $1,000 | −$60,000 | −98.36% |
| Q1 2017 | 2017-03-31 | $57,000 | −$80,000 | −58.39% |
| Q4 2016 | 2016-12-31 | $9,000 | −$62,000 | −87.32% |
| Q3 2016 | 2016-09-30 | $24,000 | −$33,000 | −57.89% |
| Q2 2016 | 2016-06-30 | $61,000 | $45,000 | +281.25% |
| Q1 2016 | 2016-03-31 | $137,000 | $130,000 | +1857.14% |
| Q4 2015 | 2015-12-31 | $71,000 | — | — |
| Q3 2015 | 2015-09-30 | $57,000 | $22,000 | +62.86% |
| Q2 2015 | 2015-06-30 | $16,000 | — | — |
| Q1 2015 | 2015-03-31 | $7,000 | — | — |
| Q3 2014 | 2014-09-30 | $35,000 | — | — |
Arcadia Biosciences capital expenditures (capex) trends
Over the last five fiscal years, Arcadia Biosciences's capital expenditures (capex) decreased from $2.3M to $0, a change of −$2.3M. The latest reported quarter, Q4 2025, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcadia Biosciences source filings ↗